Home » Stocks » PCVX

Vaxcyte, Inc. (PCVX)

Stock Price: $19.09 USD 0.42 (2.25%)
Updated May 13, 2021 4:00 PM EDT - Market closed
Market Cap 961.55M
Revenue (ttm) n/a
Net Income (ttm) -83.30M
Shares Out 51.17M
EPS (ttm) -2.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $19.09
Previous Close $18.67
Change ($) 0.42
Change (%) 2.25%
Day's Open 18.74
Day's Range 18.28 - 19.29
Day's Volume 190,282
52-Week Range 15.51 - 58.48

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

FOSTER CITY, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed ...

2 days ago - GlobeNewsWire

VAX-24 is a 24-Valent Broad-Spectrum Pneumococcal Conjugate Vaccine Leveraging Vaxcyte's Technology Platform VAX-24 is a 24-Valent Broad-Spectrum Pneumococcal Conjugate Vaccine Leveraging Vaxcyte's Tech...

3 days ago - GlobeNewsWire

FOSTER CITY, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designe...

1 month ago - GlobeNewsWire

FOSTER CITY, Calif., March 29, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designe...

1 month ago - GlobeNewsWire

U.S. vaccine developer Vaxcyte Inc on Thursday asked board chairman Moncef Slaoui to step down, a day after GlaxoSmithKline dismissed him as an independent probe found he had sexually harassed a GSK emp...

1 month ago - Reuters

Fort Worth, TX, based Investment company TPG Group Holdings (SBS) Advisors, Inc. (Current Portfolio) buys C3.ai Inc, McAfee Corp, Vaxcyte Inc, Eros STX Global Corp, Thomson Reuters Corp, sells Uber Tech...

Other stocks mentioned: ABNB, AI, APD, ESGC, MCFE, TRI
1 month ago - GuruFocus

FOSTER CITY, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designe...

1 month ago - GlobeNewsWire

FOSTER CITY, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or ...

4 months ago - GlobeNewsWire

The unicorn IPO parade is set to begin in the week ahead, with DoorDash and Airbnb leading the way. A total of six IPOs and two SPACs are scheduled to raise $7.2 billion.

Other stocks mentioned: ABNB, AI, AZEK, DASH, GBIO, RNA, UCL ...
5 months ago - Seeking Alpha

FOSTER CITY, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vacc...

5 months ago - GlobeNewsWire

FOSTER CITY, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vacc...

6 months ago - GlobeNewsWire

FOSTER CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vacc...

6 months ago - GlobeNewsWire

FOSTER CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel v...

8 months ago - GlobeNewsWire

FOSTER CITY, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- In a release issued earlier today under the same headline by Vaxcyte, Inc. (Nasdaq: PCVX), please note that in the first bullet under “Recent Hig...

9 months ago - GlobeNewsWire

FOSTER CITY, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel va...

9 months ago - GlobeNewsWire

Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Novavax.

Other stocks mentioned: BIO, FMTX, IMRA, KROS, RNA, RPTX, XBI ...
10 months ago - CNN Business

FOSTER CITY, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines design...

10 months ago - GlobeNewsWire

Shares of Vaxcyte Inc. soared 22% in their trading debut Friday, after the company's IPO priced at the top end of its price range, and was upsized to 15.6 million shares from earlier plans to sell just ...

11 months ago - Market Watch

Vaxcyte Inc. priced its initial public offering late Thursday at $16 a share, the top end of its price range, and upzied the deal to 15.6 million shares from earlier plans to sell just 14 million.

11 months ago - Market Watch

About PCVX

Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and c... [Read more...]

Industry
Biotechnology
IPO Date
Jun 12, 2020
CEO
Grant Pickering
Employees
58
Stock Exchange
NASDAQ
Ticker Symbol
PCVX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Vaxcyte stock is "Strong Buy." The 12-month stock price forecast is 48.25, which is an increase of 152.75% from the latest price.

Price Target
$48.25
(152.75% upside)
Analyst Consensus: Strong Buy